Navigation Links
Charting the Biosimilar and Biobetter Development Pipeline

NEW YORK, Sept. 20, 2012 /PRNewswire/ -- announces that a new market research report is available in its catalogue:


Charting the Biosimilar and Biobetter Development Pipeline




Biosimilar development has failed to meet expectations in recent years, but that is set to change.


With a new U.S. biosimilars approval pathway imminent, and the expiration of many top-selling biologics on the horizon, existing biosimilar developers and newcomers are highly motivated to invest in the biosimilar field and are turning their attention to more complex biologics, such as monoclonal antibodies. Global sales of biologics are projected to reach $200bn in 2014 (from $138bn in 2010), making it a potentially lucrative market for biosimilar developers.


Originator, generics, and biosimilar companies alike need to be informed about the latest development trends and to know the likely patent expiration of marketed products and status of products in development. However, market intelligence has been widely dispersed, making it very difficult for companies to assess potential competition and areas of opportunity, until now.


FirstWord has gathered the very latest intelligence from BIOPHARMA, the Orange Book, literature, industry associations, company websites, and many other secondary sources to provide a single, authoritative guide to currently marketed and in-development biosimilar products.




Report Overview

In Charting the Biosimilar and Biobetter Development Pipeline , you'll find details of currently marketed biosimilar and biobetter drugs, and all biosimilar and biobetter drugs known to be in clinical development.


Through more than 60 intuitive tables and charts, you will receive unique insights into high-level trends and significant developments, and can easily drill down to details of a specific product or therapeutic area.


Need to know when Drug X will expire? Expiration dates for reference products draw on analysis of products, active agents, and manufacturing processes to go far beyond the Orange Book.


Need to know who is developing biobetters for interferons? Access a complete list with generic and candidate names, developers, reference products, and earliest possible EU/US launch dates.


The report's author has also included concise commentary throughout, providing valuable context and key insights.


For a complete guide to biosimilars at your fingertips, download Charting the Biosimilar and Biobetter Development Pipeline today.




Key Report Features

More than 60 exclusive tables and charts, offering a complete and illuminating view of the biosimilar pipeline

Up-to-the-minute details of ALL biosimilars/biobetters known to be in development in US and EU markets, with their development status and earliest potential launch dates

Information on international biogenerics that may seek approval as biosimilars/biobetters in US and EU markets

Comprehensive list of reference products, with key sales data and expected patent expiration dates

Detailed analysis of the biosimilar pipeline and market by reference products, therapeutic area, drug class, and compound class

Reports showing the most active companies, regions, and countries

Insights into areas of most intense competition and greatest potential opportunity

Concise commentary highlighting key findings, and providing valuable market intelligence

Definitions of key terms and concepts




Key Benefits


Understand the universe of biosimilar and biobetter development

Get the complete picture of all products in the biosimilar pipeline

Know the latest status on specific biosimilar andbiobetter products of interest to you

Read about the most significant developments in every therapeutic area

Discover the levels of potential biosimilar and biobetter competition by therapy area and drug class

Analyze the size of the threat to your company's biologic portfolio

Learn which companies are potential future competitors



Key Questions Answered

When is the earliest potential launch for "Biosimilar X"?

What biosimilars are being developed in each therapeutic area, drug class, and compound class?

Which reference products are most targeted by biosimilar and biobetter developers?

Is the reference product sales value the key factor shaping biosimilar development priorities?

Which therapy areas are going to experience the most and fewest biosimilar entries?

Which companies are most active in the biosimilar and biobetter arena?

Which biosimilar companies have been most successful in getting their products onto the market?

How many new biosimilars will be on the market by 2014?


Who Would Benefit From This Report?

Strategic executives at originator, generic, and biosimilar/biobetter development companies, especially in:


Sales and Marketing

Regulatory Affairs

IP and Patent Affairs

Market Research

Research & Development

Business Development

Medical Communications




Executive summary


Definitions and methodology

> Scope and coverage

> Glossary

> Methodology

> Patents

> Indexing by indication

> Indexing by phase of development

> Nomenclature

Reference products

> Top20 Reference Products

Biosimilars in development

> Biosimilars by earliest potential launch date — US & EU

> Biosimilars by class and earliest potential launch date in the US (total number)

> Biosimilars by class and earliest potential launch date in the EU (total number)

> Biosimilar developers countries and regions

> Biosimilars in development by drug class

> Leading biosimilar companies - number of biosimilar products in portfolio

> Biosimilar development pipelines by compound class and therapy area

Biosimilar development pipelines by compound class

> Immunomodulators

> Interferons

> mAb Immunomodulators

> Cytotoxic mAbs

> Erythropoietin


> Insulins

> Other Hormones (excluding insulins)

Biosimilar development pipelines by therapy area

> Endocrine and metabolic disorders

> Haematology

> Infectious and Parasitic Disease

> Musculoskeletal disorders

> Neurology

> Neuromuscular diseases

> Obstetrics/gynaecology

> Oncology

> Ophthalmology

Biobetters in development

> Biobetter developments by compound class and therapy area

> Biobetter development by therapy area and stage

> Biobetters by class and earliest potential launch in the US

> Biobetters by class and earliest potential launch in the EU

> Biobetter developers by compound class

Biobetter development pipeline by compound class

> Immunomodulators

> Interferons

> mAb Immunomodulators

> Cytotoxic mAbs

> Erythropoietins

> Others (Enzymes, Blood Clotting Factors)

> Other Hormones (excluding insulins)

Biobetter development pipeline by therapy area

> Autoimmune disease

> Autoinflammatory disease

> Cardiovascular diseases

> Dermatology

> Endocrine and metabolic disorder

> Haematology

> Infectious and parasitic disease

> Musculoskeletal disorders

> Neurology

> Obstetrics/gynaecology

> Oncology

> Respiratory disease

> Wound care

Product profiles




To order this report:

Biopharmaceutical Industry: Charting the Biosimilar and Biobetter Development Pipeline


Nicolas Bombourg
US: (805)652-2626
Intl: +1 805-652-2626


SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Newly released FDA draft guidelines for biosimilar drugs to be discussed at conference
2. Artificial womb unlocks secrets of early embryo development
3. REST is crucial for the timing of brain development
4. Embryonic development protein active in cancer growth
5. Scientists win $2 million to study new pathway in development and maintenance of lymphoma
6. Stomata development in plants unraveled -- a valuable discovery for environmental research
7. Promising developments in early diagnosis and treatment of mesothelioma
8. Europe meets to discuss progress in energy research and development
9. Gut microbiota transplantation may prevent development of diabetes and fatty liver disease
10. New genes contributing to autism and related neurodevelopmental disorders uncovered
11. Michael J. Fox Foundation grant to Dr. Samuel Young will provide Parkinsons drug development tools
Post Your Comments:
(Date:11/4/2015)... 2015 --> ... by Transparency Market Research "Home Security Solutions Market - Global ... - 2022", the global home security solutions market is expected to ... The market is estimated to expand at a CAGR ... 2022. Rising security needs among customers at homes, the ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
(Date:10/27/2015)... 27, 2015 Munich, Germany ... Mapping technology (ASGM) automatically maps data from mobile eye ... , so that they can be quantitatively analyzed ... Munich, Germany , October 28-29, 2015. SMI,s ... from mobile eye tracking videos created with SMI,s ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... ... November 24, 2015 , ... InSphero AG, the leading supplier ... models, has promoted Melanie Aregger to serve as Chief Operating Officer. , ... the management team and was promoted to Head of InSphero Diagnostics in ...
(Date:11/24/2015)... 2015 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) ... Pierre Laurin , President and Chief Executive Officer of ... Piper Jaffray 27 th Annual Healthcare Conference to be ... 2015. st , at 8.50am (ET) and ... the day. The presentation will be available live via a ...
(Date:11/24/2015)... , Nov. 24, 2015 HemoShear ... on discovering drugs for metabolic disorders, announced today ... to its Board of Directors (BOD). Mr. Watkins ... of Human Genome Sciences (HGS), and also served ... Jim Powers , Chairman and CEO ...
(Date:11/24/2015)... YORK , November 24, 2015 ... in a European healthcare ... which the companies will work closely together in identifying European ... unmet medical need. The collaboration is underpinned by a significant ... fund. This is the first investment by Bristol-Myers Squibb in ...
Breaking Biology Technology: